

From: Liverpool-ECMC
Sent: 07 October 2019 10:17
To: Liverpool-ECMC
Subject: Liverpool ECMC Newsletter October 2019

LIVERPOOL ECMC NEWSLETTER OCTOBER 2019

LIVERPOOL CLINICAL TRIALS CENTRE (LCTC) LAUNCH



Liverpool Clinical Trials Centre aims to improve lives through the design and delivery of innovative and high-quality, world-class clinical trials.

We are a leading UK clinical trials unit and methodological research group. We bring together a wealth of expertise built on the experience of the Liverpool Trials Collaborative which has held full registration status with the UK Clinical Research Collaboration CTU network since its establishment in 2007. We are based in the Faculty of Health and Life Sciences at the University of Liverpool, a member of the Liverpool Health Partners.

We work with NHS and commercial partners, patients and the public to contribute to the identification and evaluation of new and innovative treatments and devices.

We support the development of increased capacity for conducting clinical trials locally and nationally by encouraging the development of clinicians, health care professionals, and trials methodologists as leaders in clinical trial research.



THE SINGLE POINT OF ACCESS TO RESEARCH AND KNOWLEDGE (SPARK) LAUNCH

Liverpool Health Partners have come together to create a significant new service focusing on harmonising the services that support and underpin clinical research.

The Single Point of Access for Research & Knowledge (SPARK) will support research endeavours that can meaningfully impact on the health of the local population we serve.


The priorities, values and missions of the nine NHS organisations and four Universities have been aligned around a research focus for the first time ever! This means that we can provide more opportunities for people in Liverpool to participate in clinical trials in a way that we have never been able to previously. This also means that we can provide more effective and timely support for researchers thereby increasing research activity and research funding to Liverpool.

The launch is significant and will signify implementation of the new strategies to address local health needs utilising a holistic approach.

To find out more please email [Emma Coyle](#).

WORKSHOP REMINDER

EXPLORATION INTO THE MECHANISMS OF IMMUNE-RELATED ADVERSE EVENTS



This is a reminder that a workshop entitled "Exploration into the mechanisms of immune-related adverse events" is taking place on **Thursday 10th October** in the University of Liverpool. More details and the full agenda are available on the [website](#).

This event is free to attend. To register your attendance please e-mail livecmc@liv.ac.uk.

This workshop will be a great opportunity to hear about the latest research developments linked to the HYST study and discuss potential clinical and translational collaborations.

NEW TRIALS OPENING



- **REPLIMUNE RP2** – An Open-Label, Multicenter, Phase 1 Study of RP2 as a Single Agent and in Combination with PD1 Blockade in Patients *with Solid Tumors*

Find out more...

OPEN TRIALS

Please contact **Jennie Derham** for potential referral to these trials.

- Telephone: 0151 556 5443
- Mobile: 07554 416 293
- E-mail: ccf-tr.ecmcreferrals@nhs.net



ADVANCED SOLID TUMOURS

- **ACIT-1** – A Phase I clinical study to determine the optimal dose for the safe immune restoration and immune response of allogeneic cell immunotherapy (ACIT-1) in adult cancer patients – *All advanced solid tumours*.
- **BeiGene BGB-290-106** – A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib following Single Oral Dose Administration in Patients with Advanced and/or Metastatic Solid Tumors – *Advanced or Metastatic Solid Tumours*.
- **REPLIMUNE RP1** – An Open-Label, Multicenter, Phase 1/2 Study of RPI as a Single Agent and in Combination with Immune Checkpoint Blockade or Other

Standard of Care Regimens in Patients with Solid Tumors – *Soft tissue sarcoma, stage III-IV melanoma, triple negative breast cancer, non-small cell lung cancer and non-melanoma skin cancer.*

BREAST

- **plasmaMATCH** – A multiple parallel cohort, non-randomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening – *Advanced breast cancer.*

HEAD & NECK

- **Cambridge Brain Mets Trial 1** – A proof of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy – *Brain metastases from lung or breast primary.*
- **NICO** – Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in oral cavity cancer – *squamous cell carcinoma of the oral cavity.*
- **WISTERIA** - A Phase I trial of WEE1 inhibition with Chemotherapy and Radiotherapy as adjuvant treatment, and a Window of Opportunity trial with Cisplatin in Patients with Head and Neck Cancer – *Oral, laryngeal or hypopharyngeal squamous cell carcinoma.*

HPB / UPPER GI

- **OUTREACH** – A First-in-Human, multi-centre, open-label, Phase 1 clinical study with RNA oligonucleotide drug MTL-CEBPA to investigate its safety and tolerability in patients with advanced liver cancer (OUTREACH) – *Advanced liver cancer.*
- **POLARIS** - Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma - *Hepatocellular Carcinoma*

MELANOMA

- **CirculAting Tumour DNA gUided therapy Switch (CActUS)** – A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumour DNA in guiding a switch between targeted therapy and immune therapy in patients with *advanced cutaneous melanoma.*

NON-CTIMPS

- **HYST** – Hypersensitivity Study: A Mechanistic Investigation into Drug and Chemical Induced Hypersensitivity Reactions

- **PRIMM** – Predicting Response to Immunotherapy for Melanoma with gut Microbiome and metabolomics (the PRIMM study)
- **PROACT** – Patient Reported Opinions About Clinical Tolerability
- **SMP-2** – The Cancer Research UK Stratified Medicine Programme: Pilot Study

Find out more...

EVENTS & JOB OPPORTUNITIES

EVENTS

- **HYST Workshop (OCTOBER 2019)**
- **Successful nursing in a Phase I environment (OCTOBER 2019)**
- **PSGBI Annual Network Meeting (NOVEMBER 2019)**
- **<https://www.ecmcnetwork.org.uk/events>**

CONTACT US

If you require any information which isn't on the newsletter please contact the Liverpool ECMC Team via **e-mail**.

Copyright © 2019 Liverpool ECMC, All rights reserved.

Our mailing address is:

livecmc@liv.ac.uk